Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients
Autore:
Parquet, N; Reigneau, O; Humbert, H; Guignard, M; Ribaud, P; Socie, G; Devergie, A; Esperou, H; Gluckman, E;
Indirizzi:
Hop St Louis, Bone Marrow Unit, F-75475 Paris 10, France Hop St Louis Paris France 10 Bone Marrow Unit, F-75475 Paris 10, France Hematol Hosp Paul Brousse, Villejuif, France Hematol Hosp Paul Brousse Villejuif France l Brousse, Villejuif, France Novartis France, Rueil Malmaison, France Novartis France Rueil MalmaisonFrance France, Rueil Malmaison, France
Titolo Testata:
BONE MARROW TRANSPLANTATION
fascicolo: 9, volume: 25, anno: 2000,
pagine: 965 - 968
SICI:
0268-3369(200005)25:9<965:NOFOCA>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
VERSUS-HOST DISEASE; ACUTE GRAFT; MICROEMULSION;
Keywords:
bone marrow transplantation; cyclosporin A; pharmacokinetics;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
18
Recensione:
Indirizzi per estratti:
Indirizzo: Gluckman, E Hop St Louis, Bone Marrow Unit, 1 Ave Claude Vellefaux, F-75475 Paris 10, France Hop St Louis 1 Ave Claude Vellefaux Paris France 10 0, France
Citazione:
N. Parquet et al., "New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients", BONE MAR TR, 25(9), 2000, pp. 965-968

Abstract

Cyclosporin A (CsA) absorption is variable in bone marrow transplant (BMT)patients compromising the efficacy of graft-versus-host disease prevention. Neoral, a new microemulsion formulation of CsA which has an improved bioavailibility, increases intestinal absorption of the drug with less variablepharmacokinetic parameters in non-BMT patients. In order to predict the best dosage of Neoral when patients are switched from i.v. to oral administration we performed a randomised study comparing two oral doses, either the same or twice the last i.v. dose used after BMT. Fourteen adults were randomised around day 25 after BMT. Whole blood CSA concentrations were measured 2 and 12 h after the oral administration of Neoral on days 0, 7 and 14 to determine residual and maximum concentration, and modified whenever necessary to maintain blood level CsA concentration within therapeutic range (150-250 ng/ml). We found that patients who received twice the last i.v. dose hadbetter concentrations than patients from the other group while toxicity was identical in both groups. We conclude that doubling the last i.v. dose during the switch to oral administration of Neoral gives the best therapeuticrange concentration and should be recommended for graft-versus-host prevention.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 21:34:50